Lixte Biotechnology, a clinical-stage pharmaceutical company, closed down 16 percent Wednesday at $4.06 per share, according to Yahoo Finance, after announcing plans to allocate up to 25 percent of its reserves to bitcoin reserves.
The sell-off from LIXT comes as investors appear to be switching from bitcoin to Ethereum reserve companies, which have been outperforming the world's oldest cryptocurrency on a tailwind. Bitcoin reserve companies were popular until recently, but this has clearly contributed to ETH's recent rally as a wave of new companies have started to hold ETH.
"2025 is the year of the Ethereum reserve strategy," Danny Nelson, a research analyst at Bitwise, said in an interview.
Lixte Biotechnology closed down 16% on Wednesday after plans to invest 25% of its treasury in cryptocurrencies
2025-08-14 05:59:09
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Lixte Biotechnology周三收盘下跌16%，此前计划将财库25%资金投资加密货币Next article：
BTC跌破122000美元
